Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China

Date|2021-10-20

Related Data

HanAll Biopharma (KRX: 009420.KS) announced that its partner Harbour BioMed had completed the first dosing of the first patient in Phase 2 of batoclimab in thyroid eye disease (TED)​ in China. ​

 

For more information, please refer to the link below. 

- HBM's press release link: https://www.harbourbiomed.com/news/168.html​

NextHanAll Biopharma Reports Third Quarter 2021 Results

PrevHanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China

List